Artificial intelligence has become a possible solution to resolve the problem of loss of information when complexity of a disease increases. Obesity phenotypes are observable clinical features of drug-naive schizophrenic patients. In addition, atypical antipsychotic medications may cause these unwanted effects. Here we examined the performance of neurofuzzy modeling (NFM) in predicting weight changes in chronic schizophrenic patients exposed to antipsychotics. Two hundred and twenty inpatients meeting DSMIV diagnosis of schizophrenia, treated with antipsychotics, either typical or atypical, for more than 2 years, were recruited. All subjects were assessed in the same study period between mid-November 2003 and mid-April 2004. The baseline and first visit's physical data including weight, height and circumference were used in this study. Clinical information (Clinical Global Impression and Life Style Survey) and genotype data of five single nucleotide polymorphisms were also included as predictors. The subjects were randomly assigned into the first group (105 subjects) and second group (115 subjects), and NFM was performed by using the FuzzyTECH 5.54 software package, with a network-type structure constructed in the rule block. A complete learned model trained from merged data of the first and second groups demonstrates that, at a prediction error of 5, 93% subjects with weight gain were identified. Our study suggests that NFM is a feasible prediction tool for obesity in schizophrenic patients exposed to antipsychotics, with further improvements required.
Introduction
A good prediction tool that foresees probable outcome of a remedy is essential in medical practice. As the complexity of a system (disease) increases, information afforded by traditional mathematical models or statistical methods rapidly declines. Important factors that have major effects may be dropped simply because the researchers ignore the essentiality of the information subjectively. In the meantime, artificial intelligence (AI), a branch of computer science capable of analyzing complex data, has come into notice as a possible solution for these problems and may gradually become an alternative, if not a substitute for mathematical models and traditional statistics. The potential of AI in exploiting meaningful relationships within a data set may assist diagnosis, treatment and predicting outcome in many research scenarios.
Artificial neural network (ANN) is the most widely applied AI technique while others, such as fuzzy expert systems, evolutionary computation and hybrid intelligent systems, have started to become eminent to medical practitioners and researchers. 1 ANN consists networks of highly interconnected computer processors called 'neurons' that are capable of performing parallel computations. Its ability to learn from historical examples (data used for training the model), analyze nonlinear data, handle imprecise information and generalize to independent data set has made it a very attractive analytical and predicting tool in medical research and practice. The most popular ANN model has been the multilayer feed forward perception. These networks are made up of layers of neurons, typically an input layer, one or more middle or hidden layers and an output layer, each of which are fully connected to other layers. The neurons are connected by links, and each link has a numerical weight associated with it. A neural network 'learns' through repeated adjustments of these weights. An example of ANN application in medical genetics was demonstrated by Serretti et al. 2 The study evaluated a possible role of the serotonin transporter and tryptophan hydroxylase genes in the treatment responses of patients with mood disorders.
The fuzzy expert systems adopt a different logic. Fuzzy theory is the science of human reasoning, thinking and inference that recognizes and uses the real world phenomenon that everything is a matter of degree. In the simplest terms, fuzzy logic is an extension of binary logic that does not require crisp definitions and distinctions. Instead of assuming, everything must be defined crisply into black or white categories (binary view); it is recognized that most things in the world fall somewhere in between black and white, that is, varying shades of gray (fuzzy view). For example, for a good and poor binary classification in classic statistics, conceptually, it becomes excellent, good, quite good, no so bad, poor and so on in neuro-fuzzy modeling (NFM). In brief, fuzzy logic is a methodology that captures and uses the concept of fuzziness in a computationally effective manner. 3 The fuzzy expert systems have been modulized in many of our daily used electronics, for example, washing machine, air conditioner, cooker, and so on. An AI air conditioner can detect the appearance of a person and adjust the air speed, temperature, flow direction, and so on, according to what it has learned from the previous input signals from the sensors or controller. The fuzzy expert systems has also been applied in developing the knowledge-based prediction systems for tasks such as interpretation of sets of medical findings, syndrome differentiations, diagnosis of diseases, real-time monitoring of patient data, and so on. 4 Hybridization of artificial neural networks and fuzzy logic results in a new technique that synergizes the human-like reasoning style of fuzzy systems with the learning and connectionist structure of neural networks. [5] [6] [7] [8] The hybrid intelligent systems incorporate the human-like reasoning style of fuzzy systems through the use of fuzzy sets and a linguistic model consisting of a set of IF-THEN fuzzy rules. The main strength of these systems is that they are universal approximators with the ability to implement the interpretable IF-THEN rules. These systems are categorized generally into linguistic fuzzy modeling that is focused on interpretability and precise fuzzy modeling that is focused on accuracy. NFM represents one of the previous.
In this study, we attempted to work out an AI prediction model that foresees the risk of weight gain in individual chronic schizophrenic patients exposed to antipsychotics, by modeling available data on general demographics, routine clinical assessments and genes. Obesity is one of most common health problem worldwide and has become an economic burden to health services. 9, 10 It not only causes poorer quality and enjoyment of life, 11 obesity may also be translated into a higher rate of diabetes mellitus (DM) and chronic heart diseases.
12 Obesity and metabolic disturbances are observable clinical features of drugnaive schizophrenic patients with first-episode illness and may be an inherent part of the illness. 13 The variability in patient propensity to obesity is probably determined by a combination of factors, including types of antipsychotic used and genetic background. Although schizophrenia itself may increase the risk of obesity, compelling evidences have suggested that atypical antipsychotic medications may cause the unwanted effects. Observation of long-term antipsychotic treatments showed that different types of atypical antipsychotics have different impact on obesity. For example, use of clozapine and olanzapine, followed by risperidone in schizophrenic patients, were associated with the greatest degree of weight gain; however, quetiapine has minimal effects on weight gain and does not increase the risk of developing DM.
14 A cross-sectional study conducted in Taiwan shows that, defining BMI (body mass index; kg m À2 ) X28.6 as severe obesity and X26.4 as obesity, the prevalence of obesity among male and female schizophrenic patients was 2.74-and 2.51-fold higher than the male and female subjects of a reference population recruited for the Taiwan Nutrition and Health Survey from 1993 to 1996; 15 for severe obesity, the male and female patients were 4.66-and 3.53-fold higher. 16 The authors also noticed that the rate of severe obesity was especially high in patients treated with olanzapine but not with other atypicals. These studies prompt the importance to estimate potential risk of obesity before antipsychotic medications and follow up obese conditions of schizophrenic patients exposed to antipsychotics.
One among the few and far between attempts to use AI methods to assist clinical decision in antipsychotic medication was introduced briefly by Lin et al. 17 They investigated the potency of ANN in predicting clozapine response on schizophrenic patients, using predictor variables (input variables) of 91 patients. The variables include gender, age, baseline body weight, BMI, presence of enuresis and genotype information of a few single nucleotide polymorphisms (SNPs). The overall accuracy for test dataset (that is, subjects to be predicted) is 81.8%, while the sensitivity and specificity of the prediction are 66.7 and 87.5%, respectively. It was concluded that ANN offers a high performance in predicting the response to clozapine treatment when clinical variables and genetic information were simultaneously taken into account. While the prediction power is improved, the hidden nature of ANN hinders widespread implementations. That is to say, a model that discloses the black box of modeling details would be an advantage. NFM which combines both quantitative (that is, numerical weight or accurate) and qualitative (that is, linguistic) concepts, comprises a number of rules in parallel (each rule is in the form 'IF Input 1 is X1 AND Input 2 is X2yTHEN output 1 is Y1y' where X and Y are qualitative fuzzy labels; the labels are quantified to represent the strength or certainty of the particular input or output). 18 The parallel rules are merged using fuzzy reasoning to produce the necessary quantitative output. Whereas the basic structure of a NFM model is similar to that for ANN, its rules are entirely transparent, enabling further interpretation and validation. For this advantage, we chose NFM to model weight changes in chronic schizophrenic patients exposed to antipsychotics, and predict the weight change a month after the baseline weight. In particular, weight gain was accessed.
Materials and methods

Study population
This research protocol was approved by the Institutional Review Board of Tao-Yuan Psychiatric Hospital, file number B20030902. Two hundred and twenty Han-Chinese inpatients meeting DSMIV diagnosis of schizophrenia, treated with antipsychotics, either typical or atypical, for more than 2 years, were recruited after signing informed consent forms. They were randomly assigned into the first group and second group. Each subject was assigned a seed number by the SAS program. When the seed number of a subject was smaller than a random number chosen by the computer program, it was assigned to one group and to the other when the seed number was larger. The first group included 105 subjects (47.7% of total sample) and the second group included 115 subjects (52.3% of total sample). Inequality of the sample sizes in random grouping is possible as equality only occurs when the sample size is extremely large.
Predictor variables: demographic, clinical and genetic
Physical data including weight, height and circumference were continuously recorded for 5 months (five visits, once per month) between mid-November 2003 and mid-April 2004. However, only the baseline and first visit data were used in this study. Demographic data including age, sex and length of hospitalization were also retrieved from charts. Clinical global impression (CGI) and lifestyle survey (items examined include smoking behavior, diet patterns and exercise levels) were used to collect symptoms and lifestyle data, respectively. Type of antipsychotics used by the patients, namely typical and atypical, were also taken as a variable. Further departmentalization of the typical and atypical (that is, clozapine, olanzapine, risperidone, quetiapine, and so on) was not conducted due to the limitation of our sample size. Distributions and means of the variables mentioned above are summarized in Table 1 . A small amount of blood was drawn from each patient and DNA extracted by using traditional phenol/chloroform method. AI method does not require variables to be significant to be important as defined in traditional statistical methods. A series of genes related to obesity are being examined in our laboratory. Among those completed were five SNPs of five obesity related genes, and they were included as predictors in this study, regardless of their statistical evidences in obesity of schizophrenic patients. The five SNPs at the obesity related genes are 1438G/A promoter polymorphism at the serotonin 5-hydroxytryptamine receptor 2A (HTR2A), Ser23Cys (rs6318) at the serotonin 5-hydroxytryptamine receptor 2C (5-HT2C), Arg347Cys (rs1048101) at the adrenergic receptor alpha 1A (ADRA1A), 1291C/G at the promoter region of the adrenergic receptor alpha 2A (ADRA2A) and Trp64Arg (rs4994) at the adrenergic receptor b3 (ADRB3) genes. A few genetic association studies described statistical evidences supporting a role of the HTR2A gene in obesity related physical measurements (BMI, waist-to-hip ratio and abdominal sagittal diameter), 19 food intake in obese subjects, 20 but not with those using clinical defined obese. 21 However, negative findings were reported between the HTR2A gene and BMI in a Spanish population using a case-parent study and a matched case-control study.
22 HTR2C was first suggested as candidate susceptibility gene for antipsychotic-induced weight gain because pharmacological and behavioral studies show that the HTR2C receptor is involved in the regulation of food intake in rodents. 23 Although comprehensive human genetic studies are yet to provide concrete proofs of a role of the HTR2C gene in obesity, de Luca's 24 meta-analysis reported that a SNP of the HTR2C is consistently associated with antipsychotic induced weight gain. Currently known ADR gene members include ADRA1A (once known as ADRA1C), ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2 and ADRB3. Many studies have shown that the ADR genes contribute to obesity related phenotypes in general populations, either in males or females, or both. These include the ADRA2A, 4, 25, 27, 37, 38 Most clinically effective antipsychotics are potent ADRA1 antagonists and this may contribute to the antipsychotic effect, 39 and his has possibly raised the concerns of unwanted complications via the receptor pathways. Hsu et al. 40 reported no association between the ADRA1A gene and clozapine-induced urinary incontinence. Basile et al. 41 examined possible contributions of the ADRA1A and ADRB3 genes in weight gain induced by clozapine using a rather small sample size-80 schizophrenic patients-and found no evidence to support the hypothesis. Similarly, no statistical evidence supported an association between the ADRB3 gene and clozapine-induced body weight change in Chinese schizophrenic patients. 42 The ADRA2A gene has no association with treatment efficacy and hypersalivation in Chinese schizophrenic patients receiving clozapine treatment, 43 but is associated with weight gain in Korean schizophrenic patients receiving olanzapine treatment. 44 The Arg347Cys (rs1048101) at ADRA1A gene and the Trp64Arg (rs4994) at ADRB3 gene, were examined by using a PstI RFLP 45 and a BstOI RFLP, 46 respectively. A MspI RFLP was used to discriminate the 1291C/G at the promoter region of the ADRA2A gene, as described elsewhere. 47 The 1438G/A in the promoter region at the HTR2A gene was determined by using a MspI RFLP. 48 For the Ser23Cys (rs6318) at the HTR2C gene, we designed a BseMI RFLP to determine the genotypes. A forward primer 5 0 -CCCACCACTTACTGGCTGTT-3 0 and a reverse primer 5 0 -CTGCCATGATCACAAGGATG-3 0 were used to amplify a 580 bp fragment. The PCR product was then digested according to manufacturer instructions and analyzed on a 2.5% agarose gel. The BseMI recognizes GCAATGNN (23Ser) and cuts the PCR product into 418 and 162 bp fragments. If the sequences are GCAATCNN (23Cys), PCR product remains uncut.
Neuro-Fuzzy modeling NFM was performed by using the FuzzyTECH 5.54 software package (http://www.inform-ac.com, IN-FORM GmbH, GERMANY). There are three steps in fuzzy modeling. First, the fuzzification process that takes place at input interfaces translates the analog values (standardized values that describe the magnitude of a variable, for example, kilogram) into fuzzy values (relative magnitude comparisons, for example, larger, bigger, more, and so on), via a membership function. Second, the fuzzy inference process takes place in rule blocks, which contain the linguistic control rules used for comparing the fuzzy values. Third, the de-fuzzification process taking place at output interfaces translates the linguistic variables back to analog variables, via another membership function. The parameters associated with the membership functions change through the training process so that a representative formula with minimum errors is obtained at the end.
In this study, a network-type structure similar to that of an ANN was constructed in the rule block of NFM. This structure maps the inputs and outputs through membership functions and associated parameters. Center of maximum (COM) de-fuzzification method was used to obtain the best-compromised single weight output. Error backpropagation estimation approach was used to execute both the input and output membership functions and degree of support (DoS) estimations. A training error rate is needed to converge the modeling process so that the stimulated value is closest to expected value. In this study, the training error rate was set to 1.25% because the modeling process was observed to give the best results at this level. Training error is defined as Weight change means the proportion (%) of weight gain or weight loss when comparing the resultant weight to the baseline weight. That is to say, the statement of weight gain or weight loss only sustained when the predicted weight is larger or smaller than the baseline weight at a defined proportion. Similarly, prediction error is the proportion (%) of a predicted weight allowed to be deviated from the observed weight when the model is used as a predicting tool. Thus, the prediction error of weight gain means, to be accepted as weight gain, a predicted weight gain must be smaller than the observed weight gain by the defined proportion.
Predictor variables (demographic, clinical and genetic), which had no contribution to the convergence of the model were removed from the model by an AI expert who monitored the behavior of the training process. The final decision process is designated as fuzzy logic inference flow.
Sensitivity and specificity of NFM and logistic regression were calculated by standard definitions: 
Results
Genotype distributions
Genotype frequencies of the five SNPs are listed in Table 2 .
Linearity
The fuzzy logic inference flow of this study is shown in Figure 1 . After training with the first group, the deduced model was used to test the first group again and the second group to examine linearity of the observed and predicted values. As shown in Figures  2a and b , the first group shows smaller differences between observed and predicted weight changes (%), when compared with the second group. This is an anticipated result because the first group was used for initial training; the trained model should show a better match with its 'origin' than the other. The results suggest that the training process and parameters were reliable and further investigations might be conducted. Subjects of the first and second group were merged and a new training process unrelated to the previous trial (except the parameters), was initiated. As shown in Figure 3 , the scattered plots of observed and predicted weights are exceedingly close to the diagonal line, suggesting that the complete learned model suits the need of a predicting tool.
Prediction of weight changes using the complete learned model Allowing a prediction error at 5% and weight change defined at ± 5%, 11 cases in first group and 13 cases in second group were categorized for weight gain, while 1 case in first group and 2 cases in second group for weight loss. When the prediction error was allowed at 5% and weight change defined at ± 2.5%, 24 cases in the first group and 37 cases in second the group were categorized for weight gain, and 7 cases in the first group and 5 cases in the second group for weight loss. The number of weight gain was more frequent than weight loss in both groups and expectedly increases when the definition of weight change is looser (smaller). The results are summarized in Table 3 and Figure 4 . The trained model worked better when more subjects were entered for training and more cases of weight gain are identified when the prediction error is larger, under a defined level of weight change. When the prediction error was allowed at 5%, for example, the global predicted rate of weight gain of the second group was 82.6% when the model was trained with the first group, and increased to 93% when completely trained with both first and second group (data not shown).
Sensitivity and specificity
Concerning the small magnitude of 1-month weight change in the groups, we estimated the sensitivity and specificity of the complete learned NFM and logistic regression in predicting an increase larger than 1 kg, as an example of comparisons between AI and classic statistics. The sensitivity and specificity of NFM were 83.8 and 63.2% in the first group, and 81.5 and 72.1% in the second group, respectively. The sensitivity and specificity of logistic regression were 32.4 and 76.4%
in the first group, and 40.7 and 86.8% in the second group, respectively. Overall speaking, NFM performed better than logistic regression in sensitivity, while logistic regression performed better than NFM in specificity.
Discussion
Setting an appropriate training error is crucial for a precise modeling. We examined the model performance at different levels of training error and noticed that level of prediction error must be toned-up when examining the test samples under a more stringent criterion, or some of the predicted values could not be gained. One possible reason for this phenomenon is that the some samples to be predicted might have different nature from the modeling samples. Interestingly, training error rate of 1.25% is generally selected in the industry application of NFM, although the rate is not a golden rate. It is understood that a training error rate of 1.25% will generally allow a good learning result in most circumstances, and fits the industrial regulations and criteria of accuracy of the model. Accuracy of a predicting model may be improved by increasing the sample size in the training set so that effects from factors that reduce the power of the predicting model, such as outliners, disease heterogeneity, stratification, and so on, may be diluted. Certainly, quality of the data set contributes to the accuracy to some extents. Clinically, 7% increase in weight is defined as weight gain. However, this definition is unpractical in our study because we examined the patients on monthly basis. Number of patients would be reduced under this criterion and we can hardly see the performance of the model. Our model demonstrates a good performance for small changes (weight change defined at ± 5%) pre-clinically. In practice, a small change will be warned by clinicians before reaching the 7% increase in weight. To compare the sensitivity and specificity of NFM with traditional statistics, we chose 1 kg as the cutoff point, or otherwise, we could hardly see their performances. The reason that the sensitivity of NFM was better than logistic regression is because the NFM adjusted itself to obtain predictive values that approximate observed values, while logistic regression is not designed to do so. The slightly weaker specificity of NFM compared to logistic regression is an acceptable loss because a more sensitive prediction is needed in clinical practice.
Comparing to traditional statistics, neuro-fuzzy based algorithm overcomes the problem of lower power due to unparameterized errors. Comparing to ANN, NFM has the advantages of better training and learning circuits during modeling process, and a better accommodation to integrate unparameterized 'black box' into model prediction. As a clinical tool, neuro-fuzzy based algorithm is easy to use, however, it cannot specifically quantify each variable and its proportion of contribution to the whole outcome. This is an innate defect for all AI methods, and it is a target of improvement or it may block the methods from becoming popular in medical researches and clinical applications. Predicting the treatment outcome of a disorder or disease can be a difficult task when the causes and phenotypes are heterogeneous in nature. Psychiatric disorders are spectrum disorders. Fuzzy theory somehow matches the need of psychiatric research and clinical applications because the fuzzy logic allows the prediction model to process the data in a matter of degree. Here we only examined the performance of the NFM in predicting a 1-month body change in chronic schizophrenic subjects, or more specifically, 1-month body change recorded on mid-December. We attempted to engage 5-month physical data into the model but the resultant outcome was not satisfying. The dissatisfactory might be caused by an increase of variation when the volume of physical data expanded. This is not surprising because weight change may be affected by seasonal factors. 49, 50 Moreover, because our model is limited to sample size, many interesting departmentalized predictor variables of clinical concerns, for example, further classification atypical psychotics, were not included in the modeling process. Thus, this model is not able to answer such detailed question. To resolve the problem of increase of variation when data size expands, step-by-step exclusion of each variable with more subjects may prove effective.
Our study suggests that NFM is a feasible prediction tool for research and clinical routine. Because the structures and/or parameters change when more samples and variables are added on, the model should grow smarter, and be able to predict the outcome more precisely. NFM is theoretically an exciting and novel way of combining information from different areas. However, from the standpoint of classic statistics, it is difficult to comprehend that the genetic information that may have little relation to obesity or weight-gain may contribute to the prediction of these side effects. In view of this, the conclusions from this study are that the NFM model will create a predictive algorithm based on the information given which may not work in a different sample. In simple word, direct transplantation of a trained model to other patient groups (for example, schizophrenic patients of other hospitals), even of the same ethnic group is not recommended. Although NFM is not so friendly to be adjusted or expanded when one wishes to predict a new outcome using a trained model, this problem may be partly resolved by providing modules with specified functions by the software. 
